Impact of dietary protein on postprandial glycaemic control and insulin requirements in Type 1 diabetes: a systematic review

2019 ◽  
Vol 36 (12) ◽  
pp. 1585-1599 ◽  
Author(s):  
M. A. Paterson ◽  
B. R. King ◽  
C. E. M. Smart ◽  
T. Smith ◽  
J. Rafferty ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 1 Diabetes ◽  
Glycaemic Control ◽  
Dietary Protein ◽  
Insulin Requirements

scholarly journals The Role of Dietary Protein and Fat in Glycaemic Control in Type 1 Diabetes: Implications for Intensive Diabetes Management

2015 ◽  
Vol 15 (9) ◽  
Author(s):  
Megan Paterson ◽  
Kirstine J. Bell ◽  
Susan M. O’Connell ◽  
Carmel E. Smart ◽  
Amir Shafat ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycaemic Control ◽  
Dietary Protein ◽  
Diabetes Management ◽  
Intensive Diabetes Management

scholarly journals Protocol for systematic review of evidence on the determinants and influence of early glycaemic control in childhood-onset type 1 diabetes

2015 ◽  
Vol 4 (1) ◽  
Author(s):  
Veena Mazarello Paes ◽  
Dimitrios Charalampopoulos ◽  
Amal R. Khanolkar ◽  
David Taylor-Robinson ◽  
Russell Viner ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 1 Diabetes ◽  
Glycaemic Control ◽  
Childhood Onset ◽  
Onset Type

Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis

2020 ◽  
Vol 16 (4) ◽  
pp. 313-326 ◽  
Author(s):  
Patoulias Dimitrios ◽  
Doumas Michael ◽  
Kotsis Vasilios ◽  
Stavropoulos Konstantinos ◽  
Imprialos Konstantinos ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 1 Diabetes ◽  
Meta Analysis ◽  
Insulin Dose ◽  
Grey Literature ◽  
Body Weight Loss ◽  
Severe Hypoglycemia ◽  
Insulin Requirements ◽  
Daily Insulin Dose

Background: A few Randomized Controlled Trials (RCTs) have evaluated the use of liraglutide in Type 1 Diabetes (T1D). Through the present systematic review and meta-analysis, we aim at critically appraising and summarizing those RCTs, providing precise effect estimates. Methods: We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints. This review is reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. Results: We included 5 trials with 2,445 randomized participants. Liraglutide provided modest reductions in HbA1c, with liraglutide 1.8 mg producing the greatest decrease (MD = -0.24%, 95% CI -0.32 to -0.16, I2=0%). Significant weight reduction, up to 4.87 kg with liraglutide 1.8 mg was also observed (95% CI -5.31 to -4.43, I2=0%). Decrease in total daily insulin dose, primarily driven by a decrease in bolus insulin requirements, was demonstrated. Liraglutide decreased non-significantly the odds for severe hypoglycemia (OR=0.80, 95% CI 0.57-1.14, I2=0%), while it increased significantly the odds for gastrointestinal adverse events (for nausea, OR=4.70, 95% CI 3.68-6.00, I2=37%, and for vomiting, OR=2.50, 95% CI 1.54-4.72, I2=27%). A significant increase in heart rate was also demonstrated. No association with diabetic ketoacidosis or malignancies was identified. Conclusion: In patients with T1D, liraglutide might prove be an adjunct to insulin, improving glycemic control, inducing body weight loss and decreasing exogenous insulin requirements and severe hypoglycemia.

Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control. Reply to Schatz H [letter]

Diabetologia ◽  
2010 ◽  
Vol 54 (1) ◽  
pp. 203-204 ◽  
Author(s):  
S. Vella ◽  
L. Buetow ◽  
P. Royle ◽  
S. Livingstone ◽  
J. R. Petrie
Keyword(s):  
Type 1 Diabetes ◽  
Glycaemic Control ◽  
Insulin Requirements
Sign in / Sign up

Export Citation Format

Share Document